Show simple item record

dc.contributor.authorGolder, Anya
dc.contributor.authorNelson, Louisa
dc.contributor.authorTighe, Anthony
dc.contributor.authorBarnes, Bethany M
dc.contributor.authorCoulson-Gilmer, Camilla
dc.contributor.authorMorgan, Robert D
dc.contributor.authorMcGrail, Joanne C
dc.contributor.authorTaylor, Stephen S
dc.date.accessioned2023-01-16T14:12:41Z
dc.date.available2023-01-16T14:12:41Z
dc.date.issued2022en
dc.identifier.citationGolder A, Nelson L, Tighe A, Barnes B, Coulson-Gilmer C, Morgan RD, et al. Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors. NAR cancer. 2022 Dec;4(4):zcac036. PubMed PMID: 36381271. Pubmed Central PMCID: PMC9653014. Epub 2022/11/17. eng.en
dc.identifier.pmid36381271en
dc.identifier.doi10.1093/narcan/zcac036en
dc.identifier.urihttp://hdl.handle.net/10541/625850
dc.description.abstractHigh-grade serous ovarian cancer (HGSOC) is an aggressive disease that typically develops drug resistance, thus novel biomarker-driven strategies are required. Targeted therapy focuses on synthetic lethality-pioneered by PARP inhibition of BRCA1/2-mutant disease. Subsequently, targeting the DNA replication stress response (RSR) is of clinical interest. However, further mechanistic insight is required for biomarker discovery, requiring sensitive models that closely recapitulate HGSOC. We describe an optimized proliferation assay that we use to screen 16 patient-derived ovarian cancer models (OCMs) for response to RSR inhibitors (CHK1i, WEE1i, ATRi, PARGi). Despite genomic heterogeneity characteristic of HGSOC, measurement of OCM proliferation was reproducible and reflected intrinsic tumour-cell properties. Surprisingly, RSR targeting drugs were not interchangeable, as sensitivity to the four inhibitors was not correlated. Therefore, to overcome RSR redundancy, we screened the OCMs with all two-, three- and four-drug combinations in a multiple-low-dose strategy. We found that low-dose CHK1i-ATRi had a potent anti-proliferative effect on 15 of the 16 OCMs, and was synergistic with potential to minimise treatment resistance and toxicity. Low-dose ATRi-CHK1i induced replication catastrophe followed by mitotic exit and post-mitotic arrest or death. Therefore, this study demonstrates the potential of the living biobank of OCMs as a drug discovery platform for HGSOC.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/narcan/zcac036en
dc.titleMultiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitorsen
dc.typeArticleen
dc.contributor.departmentDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, and Manchester Cancer Research Centre, Wilmslow Road, Manchester M20 4GJen
dc.identifier.journalNAR Canceren
dc.description.noteen]
refterms.dateFOA2023-01-17T09:22:22Z


Files in this item

Thumbnail
Name:
36381271.pdf
Size:
1.026Mb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record